⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27881191 | 1.00 | SLC6A1 (0.46) | — | |
| SCHEMBL13432 | 1.00 | — | — | |
| SCHEMBL10884 | 1.00 | — | — | |
| SCHEMBL5959172 | 1.00 | SLC6A1 (0.46) | — | |
| Hydrochloric Acid SCHEMBL311314 | 0.97 | — | — | |
| Methane SCHEMBL1492450 | 0.97 | — | — | |
| Ammonia Solution, Strong SCHEMBL27842570 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL16718 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL2351518 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL916269 | 0.97 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1500 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116656634-A | Dioxygenase mutant and application thereof in synthesis of (2S, 3R) -3-hydroxy piperidine acid | 江南大学 | 2023-08-29 | — | — | CN | claimed |
| EP-4027995-B1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS SATURN INC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12637454-B2 | Heterocyclic monoacylglycerol lipase (MAGL) inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260116881-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4709720-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12570672-B2 | Macrocyclic compounds and methods of use | AMGEN INC. | 2026-03-10 | — | — | US | disclosed |
| US-12552758-B2 | Inhibitors of MLH1 and/or PMS2 for cancer treatment | Neophore Limited (GB) | 2026-02-17 | — | — | US | disclosed |
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| US-20260015350-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250361244-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE ONCOLOGY LTD (IN) | 2025-11-27 | — | — | US | disclosed |
| US-5231104-A | Anticholinergic | PFIZER INC. (US) | 1993-07-27 | — | — | US | disclosed |
| EP-0350309-B1 | PIPERIDINE DERIVATIVES | Pfizer Limited (GB) | 1992-11-11 | — | — | EP | disclosed |
| CN-1064075-A | Carbamic acid derivative and preparation method thereof | ANZURIN PHARMACEUTICAL CO LTD (JP) | 1992-09-02 | — | — | CN | disclosed |
| EP-0497303-A2 | Carbamic acid derivatives and method for preparing the same | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1992-08-05 | — | — | EP | disclosed |
| EP-0494816-A1 | 1,4-Dihydropyridine derivatives, process for their preparation and therapeutical composition containing them | LABORATOIRE L. LAFON (FR) | 1992-07-15 | — | — | EP | disclosed |
| US-5089505-A | Anticholinergic agents | PFIZER INC. (US) | 1992-02-18 | — | — | US | disclosed |
| EP-0441852-A1 | MUSCARINIC RECEPTOR ANTAGONISTS. | PFIZER LTD (GB) | 1991-08-21 | — | — | EP | disclosed |
| EP-0376358-A1 | Muscarinic receptor antagonists | PFIZER INC. (US) | 1990-07-04 | — | — | EP | disclosed |
| WO-1990005133-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | PFIZER LIMITED (GB) | 1990-05-17 | — | — | WO | disclosed |
| EP-0350309-A1 | Piperidine derivatives | Pfizer Limited (GB) | 1990-01-10 | — | — | EP | disclosed |